North American Pharmaceutical was the largest of Mckesson Corp’s 4 reported lines in fiscal 2026, at $338.25B — 84% of $403.99B.
| Segment | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North American Pharmaceutical | — | $261.37B | $305.61B | $338.25B | |||||||||||||
| U.S. Pharmaceutical | $240.62B | — | — | — | |||||||||||||
| Distribution Solutions | — | — | — | — | |||||||||||||
| North America Distribution & Services | — | — | — | — | |||||||||||||
| U.S. Pharmaceutical & Specialty Solutions | — | — | — | — | |||||||||||||
| Distribution Solutions - Direct Distribution & Services | — | — | — | — | |||||||||||||
| Oncology Multispecialty | — | $30.49B | $36.86B | $48.42B | |||||||||||||
| International | $20.60B | — | — | — | |||||||||||||
| European Pharmaceutical Solutions | — | — | — | — | |||||||||||||
| Distribution Solutions Sales To Customers Warehouses | — | — | — | — | |||||||||||||
| Distribution Solutions - Sales To Customers' Warehouses | — | — | — | — | |||||||||||||
| Other | — | — | — | — | |||||||||||||
| Medical-Surgical Solutions | $11.11B | $11.31B | $11.38B | $11.51B | |||||||||||||
| Distribution Solutions - Canada Pharmaceutical Distribution & Services | — | — | — | — | |||||||||||||
| Prescription Technology Solutions | $4.39B | $4.77B | $5.22B | $5.81B | |||||||||||||
| Medical Surgical Distribution & Services | — | — | — | — | |||||||||||||
| Distribution Solutions - Medical Surgical Distribution & Services | — | — | — | — | |||||||||||||
| Distribution Solutions - Medical-Surgical Distribution & Services | — | — | — | — | |||||||||||||
| Technology Solutions | — | — | — | — | |||||||||||||
| Technology Solutions - Services | — | — | — | — | |||||||||||||
| Technology Solutions - Software & Software Systems | — | — | — | — | |||||||||||||
| Technology Solutions - Hardware | — | — | — | — | |||||||||||||
| Total | $276.71B | $307.94B | $359.07B | $403.99B |
In fiscal 2026, which ended March 31, 2026, the 4 segments Mckesson Corp reported in this breakdown added up to $403.99B. That was up 12.5% from $359.07B in fiscal 2025. North American Pharmaceutical was the largest segment, at $338.25B or 83.7% of the total, followed by Oncology Multispecialty ($48.42B, 12.0%) and Medical-Surgical Solutions ($11.51B, 2.8%). Together, the two largest segments made up 95.7% of this total.
Compared with fiscal 2025, Oncology Multispecialty grew the fastest, rising 31.4% to $48.42B. Every sizeable segment reported in both years grew.
North American Pharmaceutical (fiscal 2024) and Oncology Multispecialty (fiscal 2024) were first reported as separate segments during this period. The table also keeps 18 segments that Mckesson Corp no longer reports, so earlier years can still be read on their original basis; use "Show 18 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2010 to 2026, as reported in Mckesson Corp's annual filings.
United States was the largest of Mckesson Corp’s 2 reported lines in fiscal 2018, at $169.94B — 82% of $208.36B.
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $142.81B | $158.26B | $164.43B | $169.94B | ||||||
| Revenues | — | — | — | — | ||||||
| Foreign | $36.24B | $32.63B | $34.11B | $38.41B | ||||||
| Other | — | — | — | — | ||||||
| International | — | — | — | — | ||||||
| Total | $179.05B | $190.88B | $198.53B | $208.36B |
In fiscal 2018, which ended March 31, 2018, the 2 regions Mckesson Corp reported in this breakdown added up to $208.36B. That was up 4.9% from $198.53B in fiscal 2017. United States was the largest region, at $169.94B or 81.6% of the total, followed by Foreign ($38.41B, 18.4%).
Compared with fiscal 2017, Foreign grew the fastest, rising 12.6% to $38.41B. Over fiscal 2015 to 2018, revenue across these regions went from $179.05B to $208.36B, a compound annual growth rate of 5.2%. United States' share of the total rose from 79.8% to 81.6% over the same years.
The table also keeps 3 regions that Mckesson Corp no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2009 to 2018, as reported in Mckesson Corp's annual filings.
Mckesson Corp (MCK) breaks its revenue down by segment and region. In fiscal 2026, its largest segment was North American Pharmaceutical, with $338.25B or 83.7% of the total, followed by Oncology Multispecialty at $48.42B (12.0%).
North American Pharmaceutical was Mckesson Corp's largest segment in fiscal 2026, with $338.25B in revenue, 83.7% of the $403.99B reported across its 4 segments.
United States was Mckesson Corp's largest region in fiscal 2018, with $169.94B in revenue, 81.6% of the $208.36B reported across its 2 regions.
Of the Mckesson Corp segments reported in both fiscal 2025 and fiscal 2026, and making up at least 2% of the total, Oncology Multispecialty grew the fastest, rising 31.4% from $36.86B to $48.42B.
Every figure is taken from Mckesson Corp's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by segment covers fiscal 2010 to 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.